Advanced Oncotherapy
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Advanced Oncotherapy generated cash of $0, which is more than the previous year. Cash used in financing activities reached the amount of $0 last year.
Cash Flow
| 2013 | -2.93M | 540.46K | 2.48M |
|---|---|---|---|
| 2014 | -6.55M | -1.30M | 9.18M |
| 2015 | -9.84M | -3.72M | 21.06M |
| 2016 | -10.92M | -9.66M | 13.08M |
| 2017 | -9.58M | -8.56M | 16.75M |
| 2018 | -1.66M | -12.07M | 14.65M |
| 2019 | -23.55M | -11.67M | 37.45M |
| 2020 | -20.24M | -7.43M | 26.74M |
| 2021 | -29.57M | -9.29M | 40.78M |
| 2022 | 0 | 0 | 0 |
AVO.L Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 4.26M | 2.31M | 3.23M | 1.01M | 56.47K | 1.44M | 8.95M | 1.46M | 148.80K | 57.63K |
Operating activities | ||||||||||
Net income | 0 | -29.49M | -25.29M | -20.79M | -21.10M | -13.66M | -10.36M | -5.84M | -6.33M | -3.43M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 2.33M | 2.33M | 2.02M | 411.13K | 365.47K | 345.37K | 33.75K | 117.61K | 82.48K |
Stock-based compensation expense | 0 | 2.62M | 1.34M | 2.00M | 0 | 1.54M | 1.90M | 1.02M | 542.59K | 30.42K |
| Deferred income tax benefit | 0 | 2.62M | 1.34M | 2.00M | 0 | 1.54M | 1.90M | 1.02M | 542.59K | 30.42K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 1.24M | 235.53K | -151.08K | 97 | -2.13M | 14.77K | -2.84M | 604 | 0 |
Inventories | 0 | -9.18M | -7.09M | -5.03M | -4.29M | -191.78K | -3.01M | -3.13M | -1.07M | -37.19K |
Accounts payable | 0 | -3.98M | 968.79K | -1.51M | -1.36M | 4.34M | 662.21K | 220.34K | -604 | 0 |
Cash generated by operating activities | 0 | -29.57M | -20.24M | -23.55M | -1.66M | -9.58M | -10.92M | -9.84M | -6.55M | -2.93M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -9.29M | -7.43M | -12.00M | -12.09M | -8.56M | -9.67M | -4.28M | -1.31M | -732.11K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.02K | 27.57K |
Cash generated by investing activities | 0 | -9.29M | -7.43M | -11.67M | -12.07M | -8.56M | -9.66M | -3.72M | -1.30M | 540.46K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 43.56M | 18.04M | 25.69M | 21.05M | 250K | 13.53M | 21.06M | 10.15M | 2.43M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -7.85M | -11.62M | 0 | -10.24M | 0 | -456.75K | 0 | -978.04K | 0 |
Cash used in financing activities | 0 | 40.78M | 26.74M | 37.45M | 14.65M | 16.75M | 13.08M | 21.06M | 9.18M | 2.48M |
Net Change In Cash | 0 | 1.94M | -917.71K | 2.22M | 956.57K | -1.39M | -7.50M | 7.49M | 1.31M | 91.17K |
Cash at end of period | 4.26M | 4.26M | 2.31M | 3.23M | 1.01M | 56.47K | 1.44M | 8.95M | 1.46M | 148.80K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |